Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, May 2004, p. 1837-1847, Vol. 48, No. 5
0066-4804/04/$08.00+0 DOI: 10.1128/AAC.48.5.1837-1847.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Tina M. Kish-Catalone,1,
Lynn R. Budgeon,2 Elizabeth B. Neely,1 Maelee Ferguson,1 Fred C. Krebs,3 Mary K. Howett,4 Mohamed Labib,5 Robert Rando,5 and Brian Wigdahl3*
Department of Microbiology and Immunology,1 Department of Pathology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033,2 Department of Microbiology and Immunology and Institute for Molecular Medicine and Infectious Disease, Drexel University College of Medicine, Philadelphia, Pennsylvania 19129,3 Department of Bioscience and Biotechnology, Drexel University, Philadelphia, Pennsylvania 19104,4 Novaflux Biosciences, Inc., Princeton, New Jersey 085405
Received 9 December 2002/ Returned for modification 20 February 2003/ Accepted 25 November 2003
Clinical trials evaluating the efficacy of nonoxynol-9 (N-9) as a topical microbicide concluded that N-9 offers no in vivo protection against human immunodeficiency virus type 1 (HIV-1) infection, despite demonstrated in vitro inactivation of HIV-1 by N-9. These trials emphasize the need for better model systems to determine candidate microbicide effectiveness and safety in a preclinical setting. To that end, time-dependent in vitro cytotoxicity, as well as in vivo toxicity and inflammation, associated with N-9 exposure were characterized with the goal of validating a mouse model of microbicide toxicity. In vitro studies using submerged cell cultures indicated that human cervical epithelial cells were inherently more sensitive to N-9-mediated damage than human vaginal epithelial cells. These results correlated with in vivo findings obtained by using Swiss Webster mice in which intravaginal inoculation of 1% N-9 or Conceptrol gel (containing 4% N-9) resulted in selective and acute disruption of the cervical columnar epithelial cells 2 h postapplication accompanied by intense inflammatory infiltrates within the lamina propria. Although damage to the cervical epithelium was apparent out to 8 h postapplication, these tissues resembled control tissue by 24 h postapplication. In contrast, minimal damage and infiltration were associated with both short- and long-term exposure of the vaginal mucosa to either N-9 or Conceptrol. These analyses were extended to examine the relative toxicity of polyethylene hexamethylene biguanide (PEHMB), a polybiguanide compound under evaluation as a candidate topical microbicide. In similar studies, in vivo exposure to 1% PEHMB caused minimal damage and inflammation of the genital mucosa, a finding consistent with the demonstration that PEHMB was >350-fold less cytotoxic than N-9 in vitro. Collectively, these studies highlight the murine model of toxicity as a valuable tool for the preclinical assessment of toxicity and inflammation associated with exposure to candidate topical microbicides.
Present address: Chesapeake Biological Laboratories, Inc., Baltimore, MD 21230.
Present address: Institute of Human Virology, University of Maryland Biotechnology Institute, Baltimore, MD 21201
This article has been cited by other articles:
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |